Bruce Booth Sells 134,720 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 134,720 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $100.51, for a total transaction of $13,540,707.20. Following the sale, the director directly owned 597,047 shares of the company’s stock, valued at approximately $60,009,193.97. This trade represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The shares were sold at an average price of $121.86, for a total value of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.98, for a total value of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total value of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total value of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total value of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total value of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.

Kymera Therapeutics Stock Down 7.2%

KYMR opened at $108.12 on Friday. The firm has a market capitalization of $8.89 billion, a P/E ratio of -30.29 and a beta of 2.02. The firm’s 50 day moving average is $84.81 and its 200-day moving average is $82.31. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.82) earnings per share. Equities analysts expect that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on KYMR shares. Citigroup raised their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. UBS Group increased their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $118.18.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KYMR. Empowered Funds LLC acquired a new position in shares of Kymera Therapeutics during the first quarter valued at $203,000. Glenmede Trust Co. NA increased its holdings in shares of Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after acquiring an additional 235 shares during the period. Amundi bought a new stake in Kymera Therapeutics in the 1st quarter valued at about $249,000. California State Teachers Retirement System lifted its position in Kymera Therapeutics by 23.0% in the 1st quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock valued at $4,688,000 after purchasing an additional 10,540 shares during the last quarter. Finally, Eagle Health Investments LP boosted its stake in Kymera Therapeutics by 7.0% during the 1st quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock valued at $12,145,000 after purchasing an additional 9,516 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.